Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Medtronic
Express Scripts
Colorcon

Last Updated: September 24, 2022

Details for Patent: 8,415,342


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,415,342 protect, and when does it expire?

Patent 8,415,342 protects BESIVANCE and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 8,415,342
Title:Besifloxacin ophthalmic composition for the treatment or control of infection
Abstract: A composition comprises besifloxacin in an amount effective for treating or controlling an infection caused by an antibiotic-resistant bacterium. Such a composition can be administered to a subject for the treatment or control of bacterial conjunctivitis caused bay an antibiotic-resistant bacterium.
Inventor(s): Tyle; Praveen (Pittsford, NY), Gupta; Pramod Kumar (Pittsford, NY), Norton; Susan E. (Rochester, NY), Brunner; Lynne (Webster, NY), Blondeau; Joseph (Saskatoon, CA)
Assignee: Bausch & Lomb Incorporated (Rochester, NY)
Application Number:12/604,422
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,415,342

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing METHOD OF TREATING OCULAR BACTERIAL INFECTIONS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,415,342

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2010051291 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Harvard Business School
Dow
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.